<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35435776</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle><i>Fusobacterium nucleatum</i> induces MDSCs enrichment <i>via</i> activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance.</ArticleTitle>
        <Pagination>
          <StartPage>989</StartPage>
          <EndPage>1003</EndPage>
          <MedlinePgn>989-1003</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2061045</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">To analyse the regulatory effect of <i>Fusobacterium nucleatum</i> (Fn) on NOD-like receptor protein 3 (NLRP3) and myeloid-derived suppressor cells (MDSCs) in oesophageal squamous cell carcinoma (ESCC) as well as its effect on cisplatin (CDDP) therapy and to explore its clinical significance.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Fn infection, NLRP3 expression and MDSCs infiltration in ESCC tissues were detected by RNAscope and immunohistochemistry (IHC). The correlation between these three factors and the clinicopathological features and survival of ESCC patients was analysed. A coculture system of human peripheral blood monocytes (PBMCs) and ESCC cells was established to simulate the tumour microenvironment. <i>In vitro</i> and <i>in vivo</i> models were used to analyse the effects of Fn on the percentage of MDSCs in the coculture system and the NLRP3 expression level and CDDP sensitivity of ESCC cells.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Fn infection was consistent with high NLRP3 expression and MDSCs enrichment in ESCC tissues. Moreover, the survival time of ESCC patients was significantly shortened under Fn infection, high NLRP3 expression and MDSCs enrichment. In the <i>in vitro</i> and <i>in vivo</i> models, Fn induced abundant enrichment of MDSCs by inducing high expression of NLRP3 in ESCC cells and reducing the sensitivity of ESCC cells to CDDP.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Fn infection can induce high expression of NLRP3 in ESCC, lead to MDSCs enrichment, weaken the body's antitumour immunity, and lead to CDDP treatment resistance. The effective elimination of Fn and the inhibition of MDSCs enrichment may provide new strategies and treatments for ESCC.HighlightsThe survival of ESCC patients with Fn infection, high NLRP3 expression and MDSCs enrichment was significantly shortened.Fn infection could cause CDDP resistance in ESCC.Fn could induce the enrichment of MDSCs in the tumour microenvironment by activating NLRP3 in ESCC cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Mengxia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Anyang Tumor Hospital, Anyang Tumor Hospital affiliated to Henan University of Science and Technology, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yiwen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Zheyuan</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Haijun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Anyang Tumor Hospital, Anyang Tumor Hospital affiliated to Henan University of Science and Technology, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dai</LastName>
            <ForeName>Ningtao</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Anyang Tumor Hospital, Anyang Tumor Hospital affiliated to Henan University of Science and Technology, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Anyang Tumor Hospital, Anyang Tumor Hospital affiliated to Henan University of Science and Technology, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Yibo</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kong</LastName>
            <ForeName>Jinyu</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment; Henan Key Laboratory of Cancer Epigenetics; Cancer Hospital, The First Affiliated Hospital（College of Clinical Medicine）of Henan University of Science and Technology, Luoyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xiaopeng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Fuyou</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Anyang Tumor Hospital, Anyang Tumor Hospital affiliated to Henan University of Science and Technology, Henan Key Medical Laboratory of Precise Prevention and Treatment of Esophageal Cancer, Anyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000070576">NLR Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005674" MajorTopicYN="Y">Fusobacterium Infections</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016967" MajorTopicYN="N">Fusobacterium nucleatum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072737" MajorTopicYN="Y">Myeloid-Derived Suppressor Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000070576" MajorTopicYN="N">NLR Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Fusobacterium nucleatum</Keyword>
        <Keyword MajorTopicYN="N">Oesophageal squamous cell carcinoma</Keyword>
        <Keyword MajorTopicYN="N">cisplatin</Keyword>
        <Keyword MajorTopicYN="N">inflammasome</Keyword>
        <Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35435776</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2061045</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
